Legend Biotech (NASDAQ:LEGN) reported a transformative fourth quarter and full year for 2025, headlined by the commercial success of its lead CAR-T therapy, CARVYKTI®.
The company announced that the CARVYKTI franchise achieved full-year profitability, a critical milestone for the cell therapy pioneer as it scales production to meet global demand for multiple myeloma treatment.
For the fourth quarter ended December 31, 2025, CARVYKTI generated approximately $555 million in net trade sales, a 66% increase compared to the $334 million reported in the same period last year.
This brought full-year sales to approximately $1.9 billion.
The surge in revenue was mirrored by a milestone in patient access, with more than 10,000 clinical and commercial patients treated to date—a doubling of the patient base within a single year.
Financially, Legend Biotech reported a positive adjusted net income of $2.5 million ($0.01 per share) for the quarter, a significant turnaround from the adjusted net loss of $59 million in Q4 2024.
The company ended the year with a robust liquidity position, holding $949 million in cash and time deposits.
Management indicated this provides a comfortable financial runway to support its goal of achieving company-wide operating profit by 2026.